Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
Les dernières actualités du Dr. Falk Pharma
Bienvenue dans notre salle de presse, qui vous fournit les dernières nouvelles, communiqués de presse, annonces d'essais cliniques, événements et bien plus encore du Dr. Falk Pharma.
Suivez-nous sur LinkedIn !
Strategic Partnership with Allianthera (Suzhou) Biopharmaceuticals
for Novel AhR Agonist Development for the Treatment of Moderate to Severe Ulcerative Colitis
Positive results from pivotal phase 3 trial on norucholic acid in PSC
The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam
EASL 2025
Join us from 7 – 10 May 2025 at the EASL Congress 2025 in Amsterdam, the Netherlands or online.
Today is World Liver Day!
Did you know that our first product back in 1960 was a therapeutic drug for the liver?
Following the footsteps of our founder - The End
Elena looks back and summarizes her journey: it's a collection of emotional encounters, funny moments, and, most of all, it's a big THANK YOU!
Back to the Future – Unleashing the Power of Established Drugs
Lunch satellite symposium on 21.02.2025 during the Congress of ECCO in Berlin
![[Translate to French:]](/fileadmin/_processed_/5/2/csm_01_AlexanderKorostylev_Blauen_kl_dfc2b9c986.jpg "[Translate to French:]")
UEG Week 2024
We look forward to seeing you on booth 46 in Vienna from October 12 – 15, 2024!
Sur les traces de notre fondateur
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
Dosing of the First United States Patient
...and expansion of the Phase 2b Study of Naronapride in Gastroparesis
EASL 2024
From 5-8 June 2024 in Milan - we look forward to seeing you (exhibition space E2)
New Addition to the Management Board
The new Technical Operations business unit will be headed up by Dr. Andreas Rascher
Corum – Place To Share
Read about yesterday's groundbreaking ceremony for the building in which our HQ will be working in as of 2026.
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication
UEG Week 2023
We look forward to seeing you on booth C1-22 in Copenhagen from October 14 – 17!
Eating should be a pleasure
What does it feel like to eat when you know that each bite will hurt when swallowing?
EoE Week 2023
We support this year’s EoE Week in order to help raise awareness for eosinophilic esophagitis.
Management change at Dr. Falk Pharma
Kai Pinkernell takes over as Managing Director Science & Innovation.
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated